Lannett Completes acquisition of Silarx Pharmaceuticals, Inc.
Wednesday, June 03, 2015
Lannett Company, Inc. announced that it has completed the acquisition of privately held, Silarx Pharmaceuticals, Inc. and a related real estate entity (together "Silarx"), a manufacturer and marketer of liquid generic pharmaceutical products. As previously announced, Lannett signed the agreement to acquire Silarx on May 15, 2015.
"Having invested time and resources in evaluating a number of potential acquisitions, we are extremely pleased that Silarx is now part of our company. Today, we are a larger, more diverse and more capable organization," said Arthur Bedrosian, chief executive officer of Lannett. "The acquisition brings a high quality, talented work force that we intend to retain and an FDA-approved manufacturing facility into which we can quickly increase utilization. Silarx also adds an exciting pipeline that includes four Abbreviated New Drug Applications (ANDAs) with Paragraph 4 certification pending at the FDA and a number of complementary products."
lannett.investorroom.com
